Amgen struck deals to bolster its oncology pipeline by acquiring Dark Blue Therapeutics and inking related European partnerships that add targeted protein degradation programs and novel cancer targets. The transactions transfer preclinical and discovery-stage assets aimed at hematologic malignancies, including candidates that degrade MLLT1/3 and other oncology targets. Company statements and deal reporting noted that Amgen paid up to several hundred million dollars plus contingent milestones to secure the programs and expertise. Amgen framed the move as a strategic acceleration of its targeted protein degradation and leukemia portfolios. Amgen said integration plans are underway and highlighted the potential to advance the acquired programs into IND-enabling studies and early clinical trials under Amgen’s R&D engine.